Delving into the Latest Updates on Ofloxacin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid, OFLX, Of1oxacin

+ [56]

Target

Bacterial DNA gyrase x Bacterial top IV

Mechanism

Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors)

Therapeutic Areas

Infectious DiseasesEye DiseasesOtorhinolaryngologic Diseases+ [1]

Active Indication

ConjunctivitisCorneal UlcerTrachoma+ [7]

Inactive Indication

Acute otitis media

Originator Organization

Daiichi Sankyo Co., Ltd.

Active Organization

Santen Pharmaceutical Co., Ltd.Allergan, Inc.

Livzon Group Livzon Pharmaceutical Factory

+ [2]

Inactive Organization

Janssen Pharmaceuticals, Inc.Daiichi Pharmaceutical Co., Ltd.

Daiichi Sankyo, Inc.

Drug Highest PhaseApproved

First Approval Date

JP (16 Apr 1985),

Bacterial InfectionsOtitis ExternaOtitis Media

RegulationOrphan Drug (JP)

Login to view timeline

Structure

Molecular FormulaC18H20FN3O4

InChIKeyGSDSWSVVBLHKDQ-UHFFFAOYSA-N

CAS Registry82419-36-1

This randomized controlled trial aims to evaluate the effectiveness of intravenous (IV) versus rectal acetaminophen for postoperative pain management in neonates. The study includes postoperative term neonates who require analgesia for at least 12 hours. The main questions the study seeks to answer are:
Does IV acetaminophen provide better pain relief compared to rectal administration in neonates? What is the time to rescue analgesia and the efficacy of pain score reduction between these two routes? The study compares 32 neonates receiving IV acetaminophen to 32 neonates administered rectal acetaminophen. Both routes are administered at equivalent bioavailable doses to ensure a fair comparison.

Start Date10 Jan 2023

Sponsor / Collaborator

Rawalpindi Medical College

NCT05302531 / RecruitingPhase 1IIT

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study

The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.

Start Date09 Dec 2022

Sponsor / Collaborator

Centre Hospitalier Regional de Nancy

[+1]

100 Clinical Results associated with Ofloxacin

Login to view more data

100 Translational Medicine associated with Ofloxacin

Login to view more data

100 Patents (Medical) associated with Ofloxacin

Login to view more data

7,360

Literatures (Medical) associated with Ofloxacin

01 May 2025·Journal of Environmental Sciences

Efficient activation of peroxymonosulfate for catalytic degradation of organic pollutants by simultaneously using low-level cobalt ions and calcium carbonate micro-particles

Article

Author: Zhu, Lihua ; Zhou, Yu ; Huang, Shuangshuang ; Wang, Nan ; Wang, Xiaobo

An efficient catalytic system was developed to remove various organic pollutants by simultaneously using low-level cobalt ions, calcium carbonate micro-particles and peroxymonosulfate (PMS). A simple base-induced precipitation was used to successfully loaded Co-centered reactive sites onto the surface of CaCO₃ microparticles. Under optimal conditions at 25 °C, 10 mg/L methylene blue (MB) could be completely degraded within 10 min with 480 µg/L Co²⁺, 0.4 g/L CaCO₃ microparticles (or 0.4 g/L Co@CaCO₃) and 0.1 g/L PMS. The MB degradation followed the pseudo first order kinetics with a rate constant of 0.583 min^-1, being 8.3, 11.5 and 53.0 times that by using Co-OH (0.07 min^-1), Co²⁺ (0.044 min^-1) and CaCO₃ (0.011 min^-1) as the catalyst, respectively. It was confirmed that there was a synergistic effect in the catalytic activity between Co species and the CaCO₃ particles but the major contributor was the highly dispersed Co species. When Co²⁺-containing simulated electroplating wastewater was used as the Co²⁺ source, not only the added MB was also completely degraded within 5 min in this catalytic system, but also the coexisting heavy metal ions were substantially removed. The presently developed method was applied to simultaneously treat organic wastewater and heavy metals wastewater. The present method was also successfully used to efficiently degrade other organic pollutants including bisphenol A, sulfamethoxazole, rhodamine B, tetrabromobisphenol A, ofloxacin and benzoic acid. A catalytic mechanism was proposed for the PMS activation by Co@CaCO₃. The surface of CaCO₃ particles favors the adsorption of Co²⁺. More importantly, the surface of CaCO₃ particles provides plentiful surface -OH and -CO₃²⁺, and these surface groups complex with Co²⁺ to produce more catalytically active species such as surface [CoOH]^-, resulting in rapid Co²⁺/Co³⁺ cycling and electron transfer. These interactions cause the observed synergistic effect between Co species and CaCO₃ particles in PMS activation. Due to good cycle stability, strong anti-interference ability and wide universality, the new method will have broad application prospects.

01 Feb 2025·Food Chemistry

High sensitivity distinguishing detection of fluoroquinolones with a cage-based lanthanide metal-organic framework in food

Article

Author: Huang, Yuanyuan ; Jia, Ruoqin ; Xu, Jun ; Jia, Lei ; Zhang, Lina ; Zhao, Dan ; Zhao, Tongqian ; Zhao, Xiaolei

Sensitive and selective detection of fluoroquinolones, especially from different sources, is challenging. This study reported an uncommon three-cage lanthanide metal-organic framework (1-Eu) with a Eu³⁺ cluster as its structural primitive using a C₂-symmetric 5,5-(Pyrazine-2,6-diyl) diisophthalic acid ligand. The 1-Eu probe effectively detected four fluoroquinolones through distinct color changes and spectral emission bands, demonstrating excellent performance with low detection limits: moxifloxacin (LOD: 9.3 nM), danofloxacin (LOD: 33.7 nM), gatifloxacin (LOD: 67.9 nM), and ofloxacin (LOD: 238.6 nM). Mechanistic studies revealed that internal filtration and photoinduced electron transfer (a-PET) effects were key factors. Furthermore, 1-Eu was successfully used to detect fluoroquinolones in food samples. Additionally, portable paper-based sensors were developed to quickly semi-quantify analyte concentrations using a smartphone color recognition app, underscoring the practical potential of this probe. This study introduces a novel methodology for the identification and detection of fluoroquinolones to enhance food safety.

01 Dec 2024·Current Microbiology

Isolation of Sphingopyxis kveilinensis sp. nov., a Potential Antibiotic-Degrading Bacterium, from a Karst Wetland

Article

Author: Deng, Jie ; Chen, Ying ; Yu, Chengjian

A Gram-stain-negative, aerobic, mesophilic, motile, rod-shaped bacterium, designated strain TUF1^T, was isolated from a karst wetland in south-west China. It was demonstrated to be capable of growing on plates containing oxytetracycline, streptomycin, or ofloxacin as the sole carbon source. Phylogenetic analysis of the 16S rRNA gene sequence revealed that this organism belongs to the genus Sphingopyxis and is closely related to S. chilensis S37^T (99.17%) and S. alaskensis RB2256^T (99.12%). The orthologous average nucleotide identity values (OrthoANIu, 84.42% and 87.53%) and digital DNA-DNA hybridization values (dDDH, 41.7% and 48.9%) between strain TUF1^T and its close relatives were all below the standard recommended threshold values for species discrimination. The genomic DNA G + C content was determined to be 64.7%. The predominant cellular fatty acids were identified as summed feature 8 (C_18:1ω7c and/or C_18:1ω6c) and summed feature 3 (C_16:1ω7c and/or C_16:1ω6c). The major polar lipids found to be diphosphatidylglycerol, phosphatidylglycerol, phosphatidylcholine, phosphatidylethanolamine, and sphingoglycolipid. The sole respiratory quinone present was ubiquinone Q10. Based on the phylogenetic, biochemical, physiological, and chemotaxonomic analyses, strain TUF1^T represents a novel species of the genus Sphingopyxis. The designation "Sphingopyxis kveilinensis sp. nov." is proposed as the name for this novel species, and the strain TUF1^T (= CGMCC1.62043^T = JCM36394^T) is designated as the type strain.

100 Deals associated with Ofloxacin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00453	Ofloxacin	S01AE01 S02AA16 J01MA01	DB01165

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis	US	Allergan, Inc.	30 Jul 1993
Corneal Ulcer	US	Allergan, Inc.	30 Jul 1993
Trachoma	JP	Santen Pharmaceutical Co., Ltd.	01 Jun 1989
Blepharitis	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Dacryocystitis	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Hordeolum	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Keratitis	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Bacterial Infections	JP	Novartis Pharma AG	16 Apr 1985
Otitis Externa	JP	Alfresa Pharma Corp.	16 Apr 1985
Otitis Media	JP	Alfresa Pharma Corp.	16 Apr 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis media	Discovery	-	Daiichi Sankyo, Inc.	01 Nov 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02528123 (CTgov)	Not Applicable	Myopia	114	Small incision lenticule extraction+Tobramycin+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+dexamethasone+Ofloxacin	iolrzythhb(viebejlide) = vhpghgrbaf sbkiamidij (rznhnxkhyw, ebtwnjcdti - xfxqagouxm) View more	-	23 Apr 2024
NCT02567825 (CTgov)	Not Applicable	Acute otitis media	250	Tympanostomy tube placement+Ofloxacin Otic (Surgical Management)	kgyvmuuyaq(cgarybdcjn) = ungabyihdw tvffndkdvd (sidadbxkej, aqkfgunuct - mjmmuajkis) View more	-	10 Dec 2021
				Ceftriaxone+Amoxicillin-Clavulanate (Non-Surgical Management)	kgyvmuuyaq(cgarybdcjn) = qgbszyshfo tvffndkdvd (sidadbxkej, caplhesjoh - jqwrgsptwq) View more
NCT02373137 (DETECT, CTgov)	Phase 4	Corneal Diseases \| Keratoplasty rejection	38	DMEK+Tropicamide+phenylephrine+prednisolone+Ofloxacin (DMEK)	gxowihaojv(hzdfkdgpcy) = apqhdqucyo fadnghiqsg (mkfakhavij, mmuuprcpao - opscjgogqx) View more	-	02 Jul 2019
				DSAEK+Tropicamide+phenylephrine+prednisolone+Ofloxacin (DSAEK)	xghuauqhiq(djyrcjwcff) = rbqryhplum nujqpknfzw (wworkuewbh, fjzichzfmj - qzjshlfpsh) View more
ISRCTN63006567 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Typhoid Fever	627	Gatifloxacin	(arntwpmwjn): HR = 0.81 (95% CI, 0.25 - 2.65), P-Value = 0.73 View more	Negative	01 Jan 2013
				Ofloxacin
IAS2009	Not Applicable	Tuberculosis \| Acquired Immunodeficiency Syndrome	8	ofloxacin (Patients with multi-drug resistant tuberculosis)	vdzuueghfn(zerradjccl) = uzfshyorzi tpcrrwpsaj (yfzwedltwy ) View more	-	01 Jan 2009
				ofloxacin (Patients co-infected with multi-drug resistant tuberculosis and HIV/AIDS)	vdzuueghfn(zerradjccl) = pwbmpyipru tpcrrwpsaj (yfzwedltwy ) View more
ASCO2008	Not Applicable	Febrile Neutropenia	123	Oral ofloxacin and amoxicillin-clavulanate	(hafhetvpxc) = gxvkosdytr zuihzxzkbv (cppkjdbryh ) View more	-	20 May 2008
				Intravenous ceftriaxone and amikacin	(hafhetvpxc) = wgyqydvutw zuihzxzkbv (cppkjdbryh ) View more
63459 (ARVO2007)	Not Applicable	-	-	Moxifloxacin Ophthalmic Solution	xjqblvpnre(daoolegdlq) = zwwguzckrd dbvgaeukjr (xawixitxav )	Positive	01 May 2007
				Levofloxacin Ophthalmic Solution	xjqblvpnre(daoolegdlq) = pcqkltkizt dbvgaeukjr (xawixitxav )
ISRCTN11871179 (Pubmed \| BMC Infect Dis)	Not Applicable	Brucellosis	-	Ofloxacin plus rifampicin	jjlhnzoxdd(rkksjzxdgh) = csxezkojgw hruzcaafeh (fxatwxfaaw, 48 - 216)	-	23 Jun 2004
				Doxycycline plus rifampicin	jjlhnzoxdd(rkksjzxdgh) = zlxihkhvgl hruzcaafeh (fxatwxfaaw, 48 - 262)
ARVO2004	Not Applicable	Eye Infections, Bacterial	532	Gatifloxacin	mmbrvivbwg(cfdqffidxg) = apvqtfevfl smlxwumudr (mcfsjpzyxg )	-	01 May 2004
				Ciprofloxacin	mmbrvivbwg(cfdqffidxg) = zwnrfrxqbl smlxwumudr (mcfsjpzyxg )
PA031 (AAO2003)	Not Applicable	-	206	Levofloxacin	kzwolliusk(oyfwfwqiqx) = xsdxyrixhf bqnsmvlkdu (qegyszkmap )	Positive	17 Nov 2003
				Norfloxacin	kzwolliusk(oyfwfwqiqx) = xwmgtsnxsn bqnsmvlkdu (qegyszkmap )